Clinical trial NCT05298423: Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
Official title: Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Carcinoma, Non-Small-Cell Lung
Keywords: Programmed Cell Death-1 (PD1, PD-1)
Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1)
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2022-03-28
Enrollment: 611
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Researchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and live longer overall than people who receive durvalumab.

Detailed description: As of protocol amendment 4, participants receiving combination vibostolimab and pembrolizumab (MK-7684A) discontinued treatment due to lack of efficacy observed in other MK-7684A studies, and are given the option to transition to durvalumab therapy.

Eligibility criteria: The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion Criteria

* Has pathologically (histologically or cytologically) confirmed diagnosis of NSCLC.
* Has Stage IIIA, IIIB, or IIIC NSCLC by American Joint Committee on Cancer Version 8
* Is determined to have unresectable, Stage III NSCLC as documented by a multidisciplinary tumor board or by the treating physician in consultation with a thoracic surgeon
* Has no evidence of metastatic disease, indicating Stage IV NSCLC, in whole-body fluorodeoxyglucose (FDG)-positron emission tomography (PET) or FDG-PET/ computed tomography (CT) and CT or magnetic resonance imaging (MRI) scans of diagnostic quality of chest, abdomen, pelvis and brain
* Has measurable disease as defined by RECIST 1.1, with at least 1 lesion being appropriate for selection as a target lesion, as determined by local site investigator/radiology review
* Has not received prior treatment (chemotherapy, targeted therapy, or radiotherapy) for their Stage III NSCLC
* Has provided tumor tissue sample (tissue biopsy \[core, incisional, or excisional\])
* Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 assessed within 7 days prior to the first administration of study intervention
* Has a life expectancy of at least 6 months

Exclusion Criteria

* Has small cell lung cancer (SCLC) or tumors with the presence of small cell elements. Mixed squamous/nonsquamous tumors are eligible
* Has received prior radiotherapy to the thorax, including radiotherapy to the esophagus, mediastinum, or for breast cancer
* Has received major surgery (with the exception of replacement of vascular access) within 4 weeks before randomization. If the participant had a major operation, the participant must have recovered adequately from the procedure and/or any complications from the operation before starting study intervention
* Is expected to require any other form of antineoplastic therapy, while on study
* Has received colony-stimulating factors (e.g., Granulocyte Colony-Stimulating Factor \[G-CSF\], Granulocyte Macrophage Colony-Stimulating Factor \[GM-CSF\], or recombinant erythropoietin) within 28 days prior to the first dose of study intervention
* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication
* Has a known additional malignancy that is progressing or has required active treatment within the past 5 years
* Has an active autoimmune disease that has required systemic treatment in past 2 years
* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
* Has an active infection requiring systemic therapy
* Has a known history of human immunodeficiency virus (HIV) infection
* Has a known history of Hepatitis B (defined as hepatitis B surface antigen \[HBsAg\] reactive) or known active Hepatitis C virus (defined as HCV ribonucleic acid \[RNA\] qualitative is detected) infection
* Has had an allogenic tissue/solid organ transplant

Pemetrexed-specific Criteria:

* Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 grams per day, for at least 2 days (5 days for long-acting agents \[for example, piroxicam\]) before, during, and for at least 2 days after administration of pemetrexed
* Is unable/unwilling to take folic acid, vitamin B12, and dexamethasone

Primary outcomes:
measure: Number of Participants Who Experience at Least One Adverse Event (AE)
timeFrame: Up to approximately 48 months
measure: Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)
timeFrame: Up to approximately 48 months
Secondary outcomes:
Other outcomes:
Locations:
city: Long Beach
country: United States
facility: VA Long Beach Healthcare System ( Site 2831)
state: California
city: Los Angeles
country: United States
facility: VA West Los Angeles Medical Center ( Site 2808)
state: California
city: Hollywood
country: United States
facility: Millennium Oncology Research Clinic ( Site 2801)
state: Florida
city: Orange City
country: United States
facility: Mid Florida Hematology and Oncology Center ( Site 2800)
state: Florida
city: Tampa
country: United States
facility: Moffitt Cancer Center ( Site 2818)
state: Florida
city: Chicago
country: United States
facility: University of Chicago Medical Center ( Site 2828)
state: Illinois
city: Indianapolis
country: United States
facility: Franciscan St. Francis Health ( Site 2812)
state: Indiana
city: Baltimore
country: United States
facility: MFSMC-HJWCI ( Site 2804)
state: Maryland
city: Boston
country: United States
facility: Boston Medical Center ( Site 2829)
state: Massachusetts
city: Worcester
country: United States
facility: University of Massachusetts Chan Medical School ( Site 2815)
state: Massachusetts
city: Columbia
country: United States
facility: University of Missouri Hospital ( Site 2839)
state: Missouri
city: Springfield
country: United States
facility: Cox Medical Center North-Cox Medical Center/Hulston Cancer Center/ Radiation Oncology ( Site 2837)
state: Missouri
city: New Brunswick
country: United States
facility: Rutgers Cancer Institute of New Jersey ( Site 2805)
state: New Jersey
city: New York
country: United States
facility: Icahn School of Medicine at Mount Sinai ( Site 2821)
state: New York
city: White Plains
country: United States
facility: White Plains Hospital ( Site 2835)
state: New York
city: Portland
country: United States
facility: Kaiser Permanente Northwest-Central Interstate--Oncology ( Site 2816)
state: Oregon
city: Lancaster
country: United States
facility: Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 2827)
state: Pennsylvania
city: Philadelphia
country: United States
facility: Thomas Jefferson University - Clinical Research Institute ( Site 2813)
state: Pennsylvania
city: Houston
country: United States
facility: Millennium Research & Clinical Development ( Site 2811)
state: Texas
city: Temple
country: United States
facility: Central Texas Veterans health care-Oncology & Hematology ( Site 2819)
state: Texas
city: Tacoma
country: United States
facility: MultiCare Health System ( Site 2817)
state: Washington
city: Rio Cuarto
country: Argentina
facility: Instituto Médico Río Cuarto ( Site 3600)
state: Cordoba
city: Rosario
country: Argentina
facility: Sanatorio Parque ( Site 3602)
state: Santa Fe
city: Caba
country: Argentina
facility: Clinica Adventista Belgrano ( Site 3601)
city: Canberra
country: Australia
facility: Canberra Hospital ( Site 0010)
state: Australian Capital Territory
city: Hobart
country: Australia
facility: Icon Cancer Centre Hobart ( Site 0003)
state: Tasmania
city: Ballarat Central
country: Australia
facility: Ballarat Health Services-Medical Oncology ( Site 0002)
state: Victoria
city: Frankston
country: Australia
facility: Frankston Hospital-Oncology and Haematology ( Site 0009)
state: Victoria
city: Melbourne
country: Australia
facility: St Vincent's Hospital-Oncology Clinical Trials ( Site 0005)
state: Victoria
city: Porto Alegre
country: Brazil
facility: Hospital Nossa Senhora da Conceição ( Site 0111)
state: Rio Grande Do Sul
city: Rio de Janeiro
country: Brazil
facility: Instituto de Educação, Pesquisa e Gestão em Saúde ( Site 0105)
city: Sao Paulo
country: Brazil
facility: A. C. Camargo Cancer Center-CAPEC ( Site 0102)
city: Temuco
country: Chile
facility: James Lind Centro de Investigacion del Cancer ( Site 0202)
state: Araucania
city: Concepcion
country: Chile
facility: Biocenter ( Site 0208)
state: Biobio
city: Santiago
country: Chile
facility: FALP-UIDO ( Site 0205)
state: Region M. De Santiago
city: Santiago
country: Chile
facility: Centro de Oncología de Precisión ( Site 0209)
state: Region M. De Santiago
city: Santiago
country: Chile
facility: Bradfordhill ( Site 0200)
state: Region M. De Santiago
city: Viña del Mar
country: Chile
facility: ONCOCENTRO APYS-ACEREY ( Site 0203)
state: Valparaiso
city: Beijing
country: China
facility: Beijing Cancer hospital-intrathoratic deparmtment II ( Site 0328)
state: Beijing
city: Beijing
country: China
facility: Beijing Cancer hospital-Oncology Radiotherapy Department ( Site 0309)
state: Beijing
city: Beijing
country: China
facility: Beijing Peking Union Medical College Hospital-pneumology department ( Site 0300)
state: Beijing
city: Chongqing
country: China
facility: Army Medical Center of People's Liberation Army-Oncology Department ( Site 0321)
state: Chongqing
city: Fuzhou Fujian
country: China
facility: Fujian Medical University Union Hospital-1 Bingfanglou ( Site 0330)
state: Fujian
city: Fuzhou
country: China
facility: Fujian Provincial Cancer Hospital ( Site 0316)
state: Fujian
city: Xiamen
country: China
facility: The First Affiliated hospital of Xiamen University-oncology ( Site 0317)
state: Fujian
city: Guangzhou
country: China
facility: Southern Medical University Nanfang Hospital-Department of Oncology ( Site 0336)
state: Guangdong
city: Shijiazhuang
country: China
facility: Fourth Hospital of Hebei Medical University ( Site 0331)
state: Hebei
city: Zhengzhou
country: China
facility: Henan Cancer Hospital ( Site 0333)
state: Henan
city: Wuhan
country: China
facility: Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 0315)
state: Hubei
city: Wuhan
country: China
facility: Hubei Cancer Hospital ( Site 0311)
state: Hubei
city: Changsha
country: China
facility: Xiangya Hospital Central South University-Oncology department ( Site 0310)
state: Hunan
city: Changsha
country: China
facility: Hunan Cancer Hospital ( Site 0307)
state: Hunan
city: Suzhou
country: China
facility: The Second Affiliated Hospital of Soochow University ( Site 0314)
state: Jiangsu
city: Zhenjiang
country: China
facility: Affiliated Hospital of Jiangsu University ( Site 0305)
state: Jiangsu
city: Changchun
country: China
facility: Jilin Cancer Hospital-oncology department ( Site 0319)
state: Jilin
city: Jinan
country: China
facility: Shandong Provincial Hospital ( Site 0326)
state: Shandong
city: Qingdao
country: China
facility: Qingdao Central Hospital-Endocrinology ( Site 0332)
state: Shandong
city: Shanghai
country: China
facility: Shanghai Chest Hospital-Radiotherapy Department ( Site 0306)
state: Shanghai
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center ( Site 0304)
state: Shanghai
city: Shanghai
country: China
facility: Shanghai Pulmonary Hospital-Radiotherapy department ( Site 0335)
state: Shanghai
city: Taiyuan
country: China
facility: Shanxi Cancer Hospital-Pulmonology ( Site 0322)
state: Shanxi
city: Cheng Du
country: China
facility: West China Hospital of Sichuan University ( Site 0324)
state: Sichuan
city: Tianjin
country: China
facility: Tianjin Cancer Hospital ( Site 0329)
state: Tianjin
city: Hangzhou
country: China
facility: Hangzhou Cancer Hospital-Medical Oncology ( Site 0302)
state: Zhejiang
city: Hangzhou
country: China
facility: The Second Affiliated hospital of Zhejiang University school of medicine ( Site 0301)
state: Zhejiang
city: Hangzhou
country: China
facility: Zhejiang Cancer Hospital ( Site 0308)
state: Zhejiang
city: San José
country: Costa Rica
facility: CIMCA ( Site 0501)
state: San Jose
city: San José
country: Costa Rica
facility: PROCLINICAL Pharma ( Site 0504)
state: San Jose
city: Santa Ana
country: Costa Rica
facility: Hospital Metropolitano - Sede Lindora ( Site 0503)
state: San Jose
city: Brno
country: Czechia
facility: Masarykuv onkologicky ustav ( Site 3500)
state: Brno-mesto
city: Ostrava
country: Czechia
facility: Fakultni nemocnice Ostrava-Klinika onkologicka ( Site 3502)
state: Moravskoslezsky Kraj
city: Santo Domingo
country: Dominican Republic
facility: Instituto de Oncologia ( Site 3003)
state: Distrito Nacional
city: Distrito Nacional
country: Dominican Republic
facility: Onconet ( Site 3002)
state: Santo Domingo
city: Chemnitz
country: Germany
facility: Klinikum Chemnitz-Klinik für Innere Medizin IV ( Site 0607)
state: Sachsen
city: Grosshansdorf
country: Germany
facility: LungenClinic Grosshansdorf-Onkologie ( Site 0602)
state: Schleswig-Holstein
city: Kiel
country: Germany
facility: Universitaetsklinikum Schleswig-Holstein Campus Kiel-Medizinische Klinik II, Hämatologie und Onkolo
state: Schleswig-Holstein
city: Berlin
country: Germany
facility: Charité Campus Virchow-Klinikum-Department of Infectious Diseases and Pulmonary Medicine ( Site 0603
city: Athens
country: Greece
facility: Errikos Dunant Hospital Center-Second Department of Oncology and Clinical Trials Unit ( Site 0703)
state: Attiki
city: Athens
country: Greece
facility: Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 0706)
state: Attiki
city: Athens
country: Greece
facility: Sotiria Thoracic Diseases Hospital of Athens ( Site 0704)
state: Attiki
city: Athens
country: Greece
facility: Metropolitan Hospital ( Site 0702)
state: Attiki
city: Nea Kifissia
country: Greece
facility: General Oncology Hospital of Kifissia "Agioi Anargiroi"-2nd Department of Medical Oncology ( Site 07
state: Attiki
city: Heraklion
country: Greece
facility: University General Hospital of Heraklion-Internal Medicine-Oncology ( Site 0700)
state: Irakleio
city: Thessaloniki
country: Greece
facility: European Interbalkan Medical Center ( Site 0701)
city: Ciudad de Guatemala
country: Guatemala
facility: Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 0802)
city: Guatemala
country: Guatemala
facility: MEDI-K ( Site 0807)
city: Quetzaltenango
country: Guatemala
facility: Centro Regional de Sub Especialidades Médicas SA ( Site 0801)
city: Quetzaltenango
country: Guatemala
facility: Centro Medico Integral De Cancerología (CEMIC) ( Site 0805)
city: Haifa
country: Israel
facility: Rambam Health Care Campus-Oncology ( Site 1001)
city: Jerusalem
country: Israel
facility: Shaare Zedek Medical Center ( Site 1003)
city: Petah Tikva
country: Israel
facility: Rabin Medical Center ( Site 1004)
city: Ramat Gan
country: Israel
facility: Sheba Medical Center-ONCOLOGY ( Site 1000)
city: Tel Aviv
country: Israel
facility: Sourasky Medical Center ( Site 1002)
city: Napoli
country: Italy
facility: Istituto Nazionale Tumori IRCCS Fondazione Pascale-Oncologia medica Toraco-Polmonare ( Site 1107)
state: Campania
city: Roma
country: Italy
facility: Policlinico Universitario Campus Bio-Medico-Radiation Oncology ( Site 1101)
state: Lazio
city: Milan
country: Italy
facility: Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1100)
state: Lombardia
city: Monza
country: Italy
facility: Ospedale San Gerardo-ASST Monza-Oncologia ( Site 1102)
state: Lombardia
city: Pavia
country: Italy
facility: Fondazione IRCCS Policlinico San Matteo ( Site 1103)
state: Lombardia
city: Brescia
country: Italy
facility: Azienda Ospedaliera Spedali Civili di Brescia ( Site 1105)
city: Milano
country: Italy
facility: Ospedale San Raffaele ( Site 1104)
city: Matsuyama
country: Japan
facility: National Hospital Organization Shikoku Cancer Center ( Site 1211)
state: Ehime
city: Kurume
country: Japan
facility: Kurume University Hospital ( Site 1212)
state: Fukuoka
city: Kobe
country: Japan
facility: Kobe Minimally Invasive Cancer Center ( Site 1210)
state: Hyogo
city: Yokohama
country: Japan
facility: Kanagawa cancer center ( Site 1204)
state: Kanagawa
city: Natori
country: Japan
facility: Miyagi Cancer Center ( Site 1200)
state: Miyagi
city: Sendai
country: Japan
facility: Sendai Kousei Hospital ( Site 1213)
state: Miyagi
city: Niigata-shi
country: Japan
facility: Niigata Cancer Center Hospital ( Site 1205)
state: Niigata
city: Hirakata
country: Japan
facility: Kansai Medical University Hospital ( Site 1207)
state: Osaka
city: Takatsuki
country: Japan
facility: Osaka Medical and Pharmaceutical University Hospital ( Site 1208)
state: Osaka
city: Ina-machi
country: Japan
facility: Saitama Prefectural Cancer Center ( Site 1201)
state: Saitama
city: Koto
country: Japan
facility: Japanese Foundation for Cancer Research ( Site 1202)
state: Tokyo
city: Shinagawa
country: Japan
facility: Showa University Hospital ( Site 1203)
state: Tokyo
city: Osaka
country: Japan
facility: Osaka International Cancer Institute ( Site 1209)
city: Cheongju-si
country: Korea, Republic of
facility: Chungbuk National University Hospital-Internal medicine ( Site 2400)
state: Chungbuk
city: Suwon-si
country: Korea, Republic of
facility: The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 2401)
state: Kyonggi-do
city: Suwon-si
country: Korea, Republic of
facility: Ajou University Hospital-Hematology-Oncology ( Site 2402)
state: Kyonggi-do
city: Seoul
country: Korea, Republic of
facility: Severance Hospital, Yonsei University Health System-Lung Cancer Center ( Site 2403)
city: Lembah Pantai
country: Malaysia
facility: University Malaya Medical Centre-Clinical Oncology ( Site 1402)
state: Kuala Lumpur
city: George Town
country: Malaysia
facility: Hospital Pulau Pinang ( Site 1400)
state: Pulau Pinang
city: Kuala Lumpur
country: Malaysia
facility: Hospital Kuala Lumpur-Radiotherapy and Oncology ( Site 1401)
city: Mexico
country: Mexico
facility: Arké SMO S.A. de C.V. ( Site 1504)
state: Distrito Federal
city: Guadalajara
country: Mexico
facility: Actualidad Basada en la Investigación del Cáncer-Lung Cancer ( Site 1505)
state: Jalisco
city: Chihuahua
country: Mexico
facility: Centro Oncologico de Chihuahua-Unidad de Investigacion Clinica ( Site 1507)
city: Oaxaca
country: Mexico
facility: Centro de Investigacion Clinica de Oaxaca ( Site 1501)
city: Pasig
country: Philippines
facility: THE MEDICAL CITY-Cancer Research Center ( Site 3200)
state: National Capital Region
city: Quezon City
country: Philippines
facility: Veterans Memorial Medical Center-Section of Oncology ( Site 3201)
state: National Capital Region
city: Lisbon
country: Portugal
facility: Champalimaud Foundation ( Site 2003)
state: Lisboa
city: Lisbon
country: Portugal
facility: Hospital CUF Descobertas ( Site 2006)
state: Lisboa
city: Porto
country: Portugal
facility: Unidade Local de Saude de Santo António - Hospital Santo António ( Site 2004)
city: Porto
country: Portugal
facility: Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 2001)
city: Bucharest
country: Romania
facility: Centrul Medical Medicover Victoria ( Site 2106)
state: Bucuresti
city: Florești
country: Romania
facility: Amethyst Radiotherapy Center ( Site 2102)
state: Cluj
city: Craiova
country: Romania
facility: Centrul de Oncologie "Sfântul Nectarie" ( Site 2100)
state: Dolj
city: Otopeni
country: Romania
facility: Radiology Therapeutic Center ( Site 2108)
state: Ilfov
city: Timisoara
country: Romania
facility: Cabinet Medical Oncomed ( Site 2101)
state: Timis
city: Bucuresti
country: Romania
facility: Centrul Medical Neolife- Baneasa ( Site 2110)
city: Port Elizabeth
country: South Africa
facility: CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 2304)
state: Eastern Cape
city: Pretoria
country: South Africa
facility: Wilgers Oncology Centre ( Site 2301)
state: Gauteng
city: Durban
country: South Africa
facility: The Oncology Centre ( Site 2300)
state: Kwazulu-Natal
city: Richards Bay
country: South Africa
facility: Abraham Oncology ( Site 2303)
state: Kwazulu-Natal
city: Cape Town
country: South Africa
facility: Cape Town Oncology Trials ( Site 2306)
state: Western Cape
city: Barcelona
country: Spain
facility: Hospital Universitari Vall d'Hebron ( Site 2501)
state: Cataluna
city: Barcelona
country: Spain
facility: HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Sit
state: Cataluna
city: Santiago de Compostela
country: Spain
facility: CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 2502)
state: La Coruna
city: Pozuelo de Alarcon
country: Spain
facility: HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 2504)
state: Madrid, Comunidad De
city: Stanbul
country: Turkey
facility: Medipol Mega Universite Hastanesi-oncology ( Site 2611)
state: Istanbul
city: Bornova
country: Turkey
facility: Ege University Medicine of Faculty-Chest Diseases Department ( Site 2603)
state: Izmir
city: Adana
country: Turkey
facility: Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 2607)
city: Ankara
country: Turkey
facility: Ankara Gülhane Eitim ve Aratrma Hastanesi-Oncology ( Site 2602)
city: Ankara
country: Turkey
facility: Hacettepe Universitesi-oncology hospital ( Site 2605)
city: Ankara
country: Turkey
facility: Memorial Ankara Hastanesi-Medical Oncology ( Site 2609)
city: Ankara
country: Turkey
facility: Ankara City Hospital-Medical Oncology ( Site 2601)
city: Istanbul
country: Turkey
facility: TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2610)
city: Izmir
country: Turkey
facility: I.E.U. Medical Point Hastanesi-Oncology ( Site 2612)
city: Kropyvnytskyi
country: Ukraine
facility: Limited Liability Company Ukrainian Center of Tomotherapy-Department of Chemotherapy ( Site 2905)
state: Kirovohradska Oblast
city: Lviv
country: Ukraine
facility: Municipal non-profit enterprise "Lviv Territorial Medical Union "Multidisciplinary Clinical Hospital
state: Lvivska Oblast
city: Rivne
country: Ukraine
facility: Rivne Regional Clinical Hospital ( Site 2919)
state: Rivnenska Oblast
city: Vinnytsia
country: Ukraine
facility: Communal Noncommercial Enterprise "Podillia Regional Oncology Center Of Vinnytsia Regional Council"
state: Vinnytska Oblast
city: Lutsk
country: Ukraine
facility: Volyn Regional clinical hospital. Regional Medical Oncology Centre. Oncology chemotherapy department
state: Volynska Oblast
city: Kyiv
country: Ukraine
facility: Universal Clinic Oberig-Oncology Center ( Site 2916)
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Director
role: STUDY_DIRECTOR
References: